(NASDAQ: MIST) Milestone Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Milestone Pharmaceuticals's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast MIST's revenue for 2024 to be $95,868,841, with the lowest MIST revenue forecast at $95,868,841, and the highest MIST revenue forecast at $95,868,841. On average, 3 Wall Street analysts forecast MIST's revenue for 2025 to be $294,690,164, with the lowest MIST revenue forecast at $95,868,841, and the highest MIST revenue forecast at $575,213,044.
In 2026, MIST is forecast to generate $2,748,240,097 in revenue, with the lowest revenue forecast at $2,748,240,097 and the highest revenue forecast at $2,748,240,097.